share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A:超過5%持股股東披露文件(修正)-The Vanguard Group(5.40%)
美股SEC公告 ·  11/13 11:17

Moomoo AI 已提取核心訊息

The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 13, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group, a Pennsylvania-based investment adviser, stated that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc. and were not held in connection with any transaction having that purpose or effect.
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 13, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group, a Pennsylvania-based investment adviser, stated that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc. and were not held in connection with any transaction having that purpose or effect.
先鋒集團於2024年11月13日向證券交易委員會提交了修訂後的13G/A表格,表明其對bluebird bio, Inc.普通股的持有情況發生了變化。截至2024年9月30日,先鋒集團報告其擁有10,474,007股bluebird bio的有益所有權,佔該公司普通股類別的5.40%。該文件顯示,先鋒集團對87,543股有投票權,並對10,330,825股擁有唯一處置權,同時還對143,182股擁有附加的共享處置權。作爲一家位於賓夕法尼亞州的投資顧問,先鋒集團表示,這些證券的購買並非爲了改變或影響bluebird bio, Inc.的控制權,也未與任何具有該目的或效果的交易有關。
先鋒集團於2024年11月13日向證券交易委員會提交了修訂後的13G/A表格,表明其對bluebird bio, Inc.普通股的持有情況發生了變化。截至2024年9月30日,先鋒集團報告其擁有10,474,007股bluebird bio的有益所有權,佔該公司普通股類別的5.40%。該文件顯示,先鋒集團對87,543股有投票權,並對10,330,825股擁有唯一處置權,同時還對143,182股擁有附加的共享處置權。作爲一家位於賓夕法尼亞州的投資顧問,先鋒集團表示,這些證券的購買並非爲了改變或影響bluebird bio, Inc.的控制權,也未與任何具有該目的或效果的交易有關。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息